Form Type: 4

SEC EDGAR Link
Accession Number:0001735276-19-000083
Date:2019-08-06
Issuer: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Original Submission Date:

Reporting Person:

MARAGANORE JOHN
300 THIRD STREET
CAMBRIDGE, MA 02142

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-07-11 J 34 a $0.00 3,133 indirect f1
COMMON STOCK 2019-08-06 0 $0.00 189,993 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
PERFORMANCE STOCK OPTION 2015 (RIGHT TO BUY) 88.95 2019-08-06 deemed execution date A 16,250 (a) 2019-08-06 2025-12-18 common stock 16,250 $88.95 65,000 direct
PERFORMANCE STOCK OPTION 2016 (RIGHT TO BUY) 42.22 2019-08-06 deemed execution date A 6,250 (a) 2019-08-06 2026-12-20 common stock 6,250 $42.22 25,000 direct
Footnotes
IDfootnote
f1 reflects shares of alny common stock acquired by the reporting person under the alny 401(k) plan as a result of the alny 401(k) matching contribution program.
f2 on december 18, 2015, the reporting person was granted a performance based stock option to purchase shares of alny common stock. one quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. the compensation committee of the company determined that the fourth performance criterion was met effective as of august 6, 2019 and the option vested as to the final one-quarter of the shares as of such date.
f3 on december 20, 2016, the reporting person was granted a performance based stock option to purchase shares of alny common stock. one quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. the compensation committee of the company determined that the fourth performance criterion was met effective as of august 6, 2019 and the option vested as to the final one-quarter of the shares as of such date.
WhaleWisdom Logo

Elevate your investments